https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36736 Thu 02 Jul 2020 16:31:45 AEST ]]> Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41240 Sat 30 Jul 2022 12:19:30 AEST ]]> Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36719 Mon 24 Aug 2020 10:45:35 AEST ]]>